Clinical Trials Browser

Phase 1/2 × Bexarotene × 90 days × Clear all

NCT00238628 2026-06-04

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Phase 1/2 Completed

Lung Neoplasms